||EPS - Basic
||Market Cap (m)
|Software & Computer Services
Real-Time news about Ims Maxims (London Stock Exchange): 0 recent articles
|malcolmmm: Spoke to the company this afternoon, they say that as there is so little liquidity/activity in the shares because of the price they feel that 25p a share will help alot and they are hoping this will boost the share price which they feel should be some
I have a feeling they could be right|
|kemorkid: I hope they make a statement " no reason why share price should blah blah blah"...|
Not talking to anyone at IMX. Price drift with no keenness by management to redress it seems. Omagh news cheers me a lot more. Two pages in the Independent last Monday and the same article in Belfast Telegraph shows GAL is newsworthy.
|irishelf: I wonder if this will have much effect on IMX????
(Adds share price and context on NHS IT programme problems)
LONDON (AFX) - Healthcare software supplier iSOFT Group PLC said it expects
a 55 mln stg shortfall in full-year revenues due to delays to the 6.2 bln stg
modernisation of Britain's National Health Service computer systems.
The news wiped more than a third of the value off iSOFT shares in early
morning trading. At 8.15 am iSOFT shares were down 134-3/4 pence, or 37 pct, at
Delays to the ambitious National Programme for IT in the NHS, which accounts
for about 20 pct of iSOFT's revenue, has created "uncertainty" for the financial
year, iSOFT said in a trading update.
Total full-year revenue generated from iSOFT's contract as a supplier to the
NHS IT programme is expected to be around 30 mln stg, about 55 mln below
previous expectations, iSOFT said.
Operating profit will be about 45 mln stg less than originally expected, the
"(The NHS IT programme) rescheduling process has created uncertainty for
iSOFT's current financial year and, as the process is still ongoing, the company
does not now expect to recognise any revenue in respect of the delivery of new
software into the programme during the second half of the year," iSOFT said in a
"The impact of the rescheduling process is likely to be that the phasing of
revenues will be less concentrated in the earlier years of the programme than
iSOFT said overall revenues during the lifetime of the NHS IT programme
remained in line with its expectations but admitted that the longer-term
financial impact of changes to the NHS IT programme was currently unclear.
"The potential impact (of NHS IT programme changes) on future periods will
only become clear following the completion of the rescheduling process which is
expected to take place over the coming months," iSOFT said.
Analysts have long warned that problems with the NHS IT programme, which
includes the introduction of electronic patient records and new systems for
booking hospital appointments, could affect iSOFT's revenues.
However, iSOFT has previously shrugged off concerns about the NHS IT
programme and insisted that it was not affected by any delays and its contracts
remained on track.
Last year consultancy Accenture, one of the local service providers for the
NHS IT programme and an iSOFT partner in two English regions, said it expected
to lose up to 150 mln usd (82.4 mln stg) for the financial year related to its
work on the NHS.
Accenture blamed the shortfall on delays in the deployment of some of its
computer systems for the IT programme and lower than expected margins and
|bill.slygo: Nay...in truth its not my bag phoning up companies anymore on account of the lies and half truths I was fed.However I did phone Casey as it happens about
18 months ago and needless to say collapse of the share price and subsequent dilution was not the impression I was left with. I am more than happy to
recieve info from those who do know something or at least think that they do.............as it were. So as an honest scouse might have it.
" Come-head then, whats the score...our kid eh!?
PS..nice nudge today...whatever happened to Cheading? Now there is a man
who could tell more than he does!!!|
|toppro: I have held a very large quantity of these shares for 31/2 years and have heard story after story and promise after pormise that they were to anounce contracts soon or something soon is going to happen. All Sour, I am fed up listening to this for 3 years now. My feeling is I'm holding a lemon and a lot of them. I would love to proved wrong. Can anybody cast a light on the share price. Where is it going. . . . . Nowhere it looks . . .|
|magtalo: the share price is ticking up with every buy!!!!!!!!!!!!!!|
|explorer88: 166,667 shares sold at 1.5p - looks like first sale of a larger holding (one third of 500,000 shares or one sixth of one million shares).
There's only one way this share price is going, and that's down (until its suspended / placed in receivership - lacking sales and crippled with debt)|
You're correct in focusing on whether IMS will survive long enough to cash in on the NHS spending bonanza. The loan notes will help in the short term.
Whilst 5.5p and a market capitalisation of £8million may appear good value, my analysis is that there is a 75% chance that IMS will run short of funds and be sold to IDX or isoft - hence the recent rapid decline in the share price. All IMHO.|
Bought in when IMX dropped down to 6p and am still holding as a pure speculative play on IMX winning NHS business.
The way the price has been moving up recently I am getting more confident that the surprise will be on the upside rather than the downside. This company is so small (market cap £16.6m)that there would almost certainly be an exponential rise in the share price on confirmation of any major deal. Ergo, risk:reward ratio extremely favourable in my opinion - and no doubt today's major share-buyers think the same way.
Mind your eye
Ims Maxims share price data is direct from the London Stock Exchange